News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

JPT Peptide Technologies GmbH and Cancer Immunotherapy Trials Network Collaborate on Monitoring Cellular Immune Responses


4/16/2013 10:43:19 AM

BERLIN--(BUSINESS WIRE)--JPT Peptide Technologies GmbH (JPT), a wholly-owned subsidiary of BioNTech AG (Mainz, Germany), and the Cancer Immunotherapy Trials Network (CITN, Seattle, WA, USA) today agreed on the use of JPT’s PepMixTM Peptide Pool Platform to support CITN’s clinical cancer trials and cancer research related efforts.

Read at BioSpace.com


comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES